st International Congress On Natural Sciences (ICNAS-2021), Erzurum, Türkiye, 10 Eylül - 12 Kasım 2021, ss.260-264
L-asparaginase (EC 3.5.1.1) is a biopharmaceutical enzyme that catalyzes the hydrolysis of Lasparagine
to L-aspartic acid and ammonia. Currently, L-asparaginase is used clinically, for the
chemotherapeutic treatment of childhood acute lymphoblastic leukemia (ALL) and
lymphoblastic lymphoma. Recently, there had been preclinical studies showing that the antitumor
activity of L-asparaginase actually covers a wider range of cancer types (i.e., ovarian
cancer, breast cancer and glioma). L-Asparaginase also reduces acrylamide formation in food by
selectively hydrolysing asparagine to aspartic acid and ammonia without affecting other amino
acids, retaining food quality. L-Asparaginase is widely present in plants, animals and microbes
but not in humans. Microorganisms are a better source for the production of enzyme as they are
easy to cultivate and manipulate. For successful clinical applications, it is necessary to identify
glutaminase-free L-asparaginase, which is obtained from a novel producer organism. The aims
of the current study were isolation and identification of glutaminase and urease free Lasparaginase
producing novel bacteria from the digestive systems of some animals and soil. The
selection of L-asparaginase, L-glutaminase and urease producing strains was carried out by the
private plate assay containing phenol red (0.009%) as an indicator. L-asparaginase-producing
isolates that do not produce glutaminase and urease were identified by 16s rRNA sequencing of
Bacillus atrophaeus strain AspK1, Bacillus atrophaeus strain AspK3 and Brevibacterium
frigoritolerance strain AspS1.